Before Wegovy drugmaker Novo Nordisk swept in to buy Inversago Pharma for up to $1.075 billion earlier this month, the small Canadian biotech had been working toward a potential initial public offering for next year.
Novo Nordisk on Thursday said it will acquire Inversago Pharma, a privately held obesity drug maker, for up to $1.08 billion to broaden the Danish company’s blockbuster weight loss portfolio.
MONTREAL & SAN DIEGO--(BUSINESS WIRE)--Inversago Pharma Inc. (“Inversago”), a leader in the development of peripherally-acting CB1 receptor (CB1r) blockers to address complications associated with metabolic and fibrotic diseases, today announced data from its Phase 1b trial for INV-202 to be presented in a poster session at the 83rd American Diabetes Association Scientific Sessions (ADA) in San Diego. INV-202 is a potential first-in-class, peripherally-acting CB1r blocker, being developed to treat metabolic syndrome and associated complications. Phase 1b clinical results demonstrated favorable safety and tolerability as well as pharmacokinetic (PK) and pharmacodynamic (PD) effects in subjects with features of metabolic syndrome over a 28-day treatment period.
MONTREAL, Québec--(BUSINESS WIRE)--Inversago Pharma Inc. (“Inversago”), a leader in the development of peripherally-acting CB1 receptor blockers to address complications associated with metabolic and fibrotic diseases, today announced that it will present data from the Phase 1b trial for INV-202, at the 83rd American Diabetes Association Scientific Sessions taking place on June 23-26, 2023, in San Diego, California. INV-202 is a potential first-in-class, peripheral CB1r blocker, being developed to treat metabolic disorders and associated complications.
MONTREAL--(BUSINESS WIRE)--Inversago Pharma Inc. (“Inversago”), a leader in the development of peripherally-acting CB1 receptor (CB1r) blockers to address complications associated with metabolic and fibrotic diseases, today announced positive results from a proof-of-concept study of INV-202 in a mouse model of obese asthma at the American Thoracic Society (ATS) International Conference taking place from May 19-24, 2023, in Washington, D.C.
Inversago Pharma to Participate at the 2023 SVB Securities Global Biopharma Conference
Inversago Pharma Doses First Patient in Phase 2 Trial of INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease
MONTREAL--(BUSINESS WIRE)--Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced the appointment of two new board members: Ed Mathers, BSc, General Partner at New Enterprise Associates (“NEA”) and Nanna Lüneborg, PhD, MBA, General Partner at Forbion.
MONTREAL--(BUSINESS WIRE)--Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced the appointment of two new board members: Ed Mathers, BSc, General Partner at New Enterprise Associates (“NEA”) and Nanna Lüneborg, PhD, MBA, General Partner at Forbion.
MONTREAL--(BUSINESS WIRE)--Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced the completion of a Series C funding of $95 million CAD (approximately $70 million USD), led by New Enterprise Associates (“NEA”). Additional new investors Forbion’s Growth Opportunities Fund (“Forbion Growth”) and Amgen Ventures joined current investors including Forbion’s Ventures Fund IV (“Forbion Ventures”), Fonds de solidarité FTQ, Genesys Capital, AmorChem, JDRF T1D Fund and adMare BioInnovations in the financing round.